Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis
Japanese Journal of Clinical Oncology · 2026
DOI: 10.1093/jjco/hyag042 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Kazuki Nishimura und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan. Hauptthemen laut MEDLINE: Benzamides, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Androgen receptor signaling inhibitors (ARSIs) such as enzalutamide (Enz) and apalutamide (Apa), in combination with androgen deprivation therapy (ADT), are standard for metastatic hormone-sensitive prostate cancer (mHSPC). However, direct real-world comparisons, particularly in Japanese populations, are limited.
Methods
We retrospectively reviewed 227 mHSPC patients treated with Enz (n = 112) or Apa (n = 115) plus ADT. Propensity score matching (PSM) adjusted for baseline differences. Primary endpoints were prostate-specific antigen (PSA) response, time to castration resistance (TTCR), and overall survival (OS).
Results
In the matched cohort after PSM, PSA nadir <0.2 ng/ml was achieved in 63.1% of Enz-treated and 60.3% of Apa-treated patients; ≥90% PSA decline occurred 94.5% and 92.0%, respectively. TTCR and OS were similar between groups (TTCR: P = .415; OS: P = .202). Time to treatment failure (TTF) was significantly shorter with Apa than with Enz (P = .0016). Reduced-dose initiation was more frequent with Apa (22.1% vs 9.8%, P = .0118), and TTCR did not differ across subgroups stratified by treatment and starting dose (P = .8465). Adverse events (AEs) leading to treatment discontinuation were more frequent in the Apa group than in the Enz group (20.9% vs 4.5%). Second-line therapy use after treatment failure was similar (86.4% Enz vs 90.2% Apa), with abiraterone being the most common.
Conclusions
In this real-world Japanese cohort, Enz and Apa plus ADT showed comparable PSA responses, TTCR, and OS after PSM; however, Apa was associated with shorter TTF and more frequent AE-related treatment discontinuation. Reduced-dose initiation was more common with Apa without apparent TTCR disadvantage. Given the limited number of events, these findings should be interpreted with caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan.
- Department of Urology, Kawasaki Medical School, 577, Matsushima, Kurashiki City, Okayama 701-0192, Japan.
- Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461, Japan.
- Department of Urology, Fujita-Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake City, Nagoya, Aichi 470-1192, Japan.
- Department of Urology, Kindai University Faculty of Medicine, 377-2, Oono-higashi, Osakasayama City, Osaka 589-8511, Japan.
- Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192, Japan.
ORCID-Profile: Taizo Uchimoto, Fumihiko Urabe, Shunsuke Tsuduki, Kiyoshi Takahara, Takahiro Kimura, Kazumasa Komura
Zitieren
APA
Nishimura, K., Hirosuna, K., Niigawa, H., Kakumae, S., Morinaka, H., Fukuokaya, W., Yoshizawa, A., Saruta, M., Fujimoto, S., Morita, T., Yamamoto, Y., Sakamoto, M., Uchimoto, T., Maenosono, R., Tsujino, T., Nishio, K., Yoshikawa, Y., Ichihashi, A., Yamamoto, S., …, & Komura, K. (2026). Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyag042
Vancouver
Nishimura K, Hirosuna K, Niigawa H, Kakumae S, Morinaka H, Fukuokaya W, et al. Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyag042
BibTeX
@article{Nishimura2026,
author = {Nishimura, Kazuki and Hirosuna, Kensuke and Niigawa, Heima and Kakumae, Sho and Morinaka, Hirofumi and Fukuokaya, Wataru and Yoshizawa, Atsuhiko and Saruta, Masanobu and Fujimoto, Saizo and Morita, Tsuyoshi and Yamamoto, Yutaka and Sakamoto, Moritoshi and Uchimoto, Taizo and Maenosono, Ryoichi and Tsujino, Takuya and Nishio, Kyosuke and Yoshikawa, Yuki and Ichihashi, Atsushi and Yamamoto, Shutaro and Iwatani, Kosuke and Urabe, Fumihiko and Mori, Keiichiro and Yanagisawa, Takafumi and Tsuduki, Shunsuke and Takahara, Kiyoshi and Inamoto, Teruo and Fujita, Kazutoshi and Azuma, Haruhito and Kimura, Takahiro and Komura, Kazumasa},
title = {Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
doi = {10.1093/jjco/hyag042}
}
EUVIMED